Biotech entity

USAID

organization

USAID is most often covered alongside CDC, which appears in 1 of these 2 stories. That works out to roughly 0.1 stories per week across a 136-day span. The 7.5 average consequence score is above the beat benchmark of 6.2 in the same window.

Last mentioned: Feb 27, 2026

Entity pulse

Recent coverage · USAID

2 stories
7.5 avg impact
50% positive
50% negative

Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.

  • 50% positive
  • 50% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about USAID

USAID is most often covered alongside CDC, which appears in 1 of these 2 stories. That works out to roughly 0.1 stories per week across a 136-day span. The 7.5 average consequence score is above the beat benchmark of 6.2 in the same window. Each story carries 4.5 original sources on average, compared with 3.5 for the broader beat in this window. funding accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. This profile follows 2 Biotech stories mentioning USAID across the period from February 27, 2026 to July 12, 2026.

Stories tracked
2
Per week
0.1
Sources per story
4.5

Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 439 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering USAID. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning USAID 2

Pharma Strongly negative

PEPFAR Overhaul Puts Global Antiretroviral Supply Chain at Risk: 8.7M Patients Impacted

For biopharma manufacturers, the restructuring of PEPFAR and the September award expirations threaten high-volume procurement contracts and stable antiretroviral demand. The cliff could disrupt clinical trial infrastructure, inventory planning, and generic drug production that have relied on predictable US funding for over two decades.

4 sources

Source: edition.cnn.com · cbs58.com

Funding Positive

US and DR Congo Ink Landmark $1.2 Billion Health Partnership Agreement

The United States and the Democratic Republic of the Congo have finalized a $1.2 billion health partnership aimed at strengthening healthcare infrastructure and disease surveillance. This multi-year commitment focuses on global health security, infectious disease control, and improving maternal and child health outcomes.

5 sources

USAID is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.